CorMedix Shares Hit 52-Week Low After DaVita Flags 2027 Reimbursement Drop
CorMedix shares fell nearly 26% on Friday, hitting a fresh 52-week low after DaVita warned that Medicare reimbursement for DefenCath could drop sharply in 2027.
Shares of CorMedix (CRMD) tumbled nearly 26% on Friday, hitting a fresh 52-week low, as investors reacted to remarks from dialysis giant DaVita (DVA) about how Medicare payments for CorMedix’s flagship product, DefenCath, will evolve.DefenCath is a solution used to help prevent serious bloodstream…